Sandro CarraraSandro Carrara a été nommé IEEE Fellow pour ses remarquables réalisations dans le domaine de la conception de biocapteurs CMOS à l'échelle nanométrique. Il a également reçu le prix "IEEE Sensors Council Technical Achievement Award" en 2016 pour son leadership dans le domaine émergent du co-design des interfaces Bio/Nano/CMOS. Il est un Professeur titulaire à l' EPFL à Lausanne (Suisse) et responsable du groupe de recherche "Bio/CMOS Interfaces" (BCI). Il est ancien professeur de biocapteurs optiques et électriques au Département de génie électrique et de biophysique (DIBE) de l'Université de Gênes (Italie) et ancien professeur de nanotechnologie à l'Université de Bologne (Italie). Il est titulaire d'un doctorat en biochimie et de biophysique de l'Université de Padoue (Italie), une master en physique de l'Université de Gênes (Italie), et un diplôme en électronique de l'Institut National de Technologie à Albenga (Italie). Ses intérêts scientifiques sont sur les phénomènes électriques de films nano-bio-structuré, et comprennent CMOS conception de biopuces à base de protéines et de l'ADN. Le long de sa carrière, il a publié 7 livres, l'un comme auteur avec Springer sur les interfaces Bio/CMOS et, plus récemment, un manuel de bioélectronique avec La prestigieuse Cambridge University Press. Il a également publié plus de 250 articles scientifiques et est l'auteur de 13 brevets. Il est maintenant chef rédacteur du Journal IEEE Sensors; il est également fondateur et chef rédacteur du Journal BioNanoScience par Springer, et rédacteur adjoint de IEEE Transactions on Circuits and Biomedical Systems. Il est membre du IEEE Sensors Council et de son comité exécutif. Il était membre du Conseil des gouverneurs de la IEEE Circuits And Systems Society (CASS). Il a été nommé IEEE conférencier émérite pour les années 2017-2019 pour le Conseil IEEE Sensors, et de la société CASS pour les années 2013-2014. Son travail a reçu plusieurs reconnaissances internationales: plusieurs Top-25 Hottest-articles (2004, 2005, 2008, 2009, et deux fois en 2012) publiés dans des journaux internationales très fort impact telles que Biosensors and Bioelectronics, Sensors And Actuators B, IEEE Sensors, et Thin Solid Films; un Award à une conference de l'OTAN en 1996 pour la contribution originale à la physique de la conductivité à électron unique dans les nano-particules; six "Best Paper Awards" pour des articles présentés à la conférence IEEE Sensors Conference en 2019 (Montreal), IEEE NGCAS en 2017 (Genoa), MOBIHEALTH en 2016 (Milan), IEEE PRIME en 2015 (Glasgow), en 2010 (Berlin) et en 2009 (Cork), un prix de la meilleure affiche au rencontre annuel de Nanotera en 2011 (Berne), et un prix de la meilleure affiche au NanoEurope Symposium en 2009 (Rapperswil). De 1997 à 2000, il a été membre d'un comité international au ELETTRA Synchrotron à Trieste. De 2000 à 2003, il était responsable scientifique d'un Programme national de recherche (PNR) dans le dépôt de nanobiotechnologie. Il était un expert internationalement estimé du comité d'évaluation de l'Académie de Finlande dans un programme de recherche pour les années 2010-2013. Il a été le président général (General Chair) de la Conférence IEEE BioCAS 2014, le premier conférence internationale dans le domaine des circuits et des systèmes pour les applications biomédicales.
Gerardo TurcattiSenior scientific level (R&D) with extensive experience in the management of multidisciplinary technological projects. Prof. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL he created in 2006. In the framework of the NCCR-Chemical Biology, he is project leader of the program ACCESS (An Academic Chemical Screening Platform for Switzerland). Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed high throughput DNA sequencing technologies currently owned by Illumina and used in the ‘Next Generation Sequencing’ instruments. Prior to this experience, Prof. Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Chemical Biology, Bio-analytical Chemistry, DNA and Protein Chemistry. Prof. Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.
Didier TronoAprès des études de médecine à l’Université de Genève et une formation clinique en pathologie, médecine interne et maladies infectieuses à Genève et au Massachusetts General Hospital de Boston, Didier Trono s’engage dans une carrière scientifique au Whitehead Institute du MIT. En 1990, il est recruté par le Salk Institute de San Diego pour lancer un centre de recherche sur le SIDA. Il rentre en Europe sept ans plus tard, avant de prendre en 2004 les rênes de la toute nouvelle faculté des Sciences de la Vie de l’EPFL, dont il orchestre le développement et qu’il dirige jusqu’en 2012. Il participe aujourd’hui activement à la coordination des efforts de la Suisse en vue de l’intégration des nouvelles technologies dans le domaine de la médecine de précision et de la santé personnalisée.
Freddy RadtkeFreddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences
Michel AguetDr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Pierre GönczyPierre Gönczy obtained his PhD from The Rockefeller University (New York, USA) in 1995 and joined the laboratory of Tony Hyman at the EMBL (Heidelberg, Germany) as a postdoctoral fellow in 1996. He started his own laboratory at ISREC in 2000. In 2005, he became Associate Professor at the EPFL School of Life Sciences, and was promoted Full Professor in 2009.
Henning Paul-Julius StahlbergPositions:
Since 2020 Prof. Physics, IPHYS, SB, EPFL, Switzerland 2009 – 2021 Prof. Structural Biology, Biozentrum, University Basel, Switzerland
2009 – 2010 Adj. Assoc. Prof. Molecular & Cellular Biology, UC Davis, CA, USA
2007 – 2009 Assoc. Prof. Molecular & Cellular Biology, UC Davis, CA, USA
2003 – 2007 Assist. Prof. Molecular & Cellular Biology, UC Davis, CA, USA
Education: 2002 Habilitation, Biozentrum, University Basel, Switzerland 1997 – 2003 Postdoctoral Fellow, Biozentrum, University Basel, Switzerland 1992 – 1997 PhD Student, EPFL, Lausanne, Switzerland 1990 – 1991 Diploma Thesis in Solid State Physics, TU Berlin, Germany 1987 – 1993 Study of Physics, TU Berlin, Germany Selected Awards & Honors: 2009 W.M.Keck Award 2004 CAREER award, NSF, USA 2002 Habilitation, University Basel, Switzerland Selected Memberships: 2008 – 2013 Chancellor’s Fellow Award, UC Davis, CA, USA 2004 – 2009 Faculty of 1000 Since 1992 Swiss Society for Optics and Microscopy (SSOM)
Matthias LütolfMatthias Lutolf is Full Professor at EPFL’s Institute of Bioengineering, with a cross appointment in the Institute of Chemical Sciences and Engineering. Lutolf was trained as a Materials Engineer at ETH Zurich where he also carried out his PhD studies (with Jeffrey Hubbell) that were awarded with an ETH medal. He continued his research training as a Post-Doctoral Fellow in Stem Cell Biology (with Helen Blau) at Stanford University. He has served as the Director of the Institute of Bioengineering from 2014 to 2018. Lutolf is an internationally recognized leader in the fields of stem cell bioengineering and tissue engineering. His research program uniquely combines stem cell biology with engineering principles and quantitative thinking. His team, composed of engineers, chemists, physicists, cell and developmental biologists, strives to develop technologies that have true biological and medicinal function and applicability. Lutolf’s work has led to more than 110 peer-reviewed scientific publications, many of which published in highly reputed journals, more than 25 patents, and the commercialization of several products. Current research in the Lutolf lab is focused on the bioengineering of miniature tissues, termed organoids, that are generated from self-organizing stem cells.
